- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05733533
A Study to Assess the Efficacy and Tolerance of HRS-2261 in Subjects With Refractory Chronic Cough
June 4, 2023 updated by: Guangdong Hengrui Pharmaceutical Co., Ltd
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Study of Efficacy and Safety of HRS-2261 in Refractory Chronic Cough
This is a phase II study that will investigate the efficacy, safety and tolerability of HRS-2261 in subjects with refractory chronic cough using a double blind, placebo controlled, randomized study design.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
304
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Honghui Wang
- Phone Number: +0518-82342973
- Email: honghui.wang@hengrui.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- The First Affiliated Hospital of Guangzhou Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- ≥18 years of age;
- Diagnosed with refractory chronic cough or chronic cough of unknown cause, with a course of disease lasting more than 1 year;
- Within 5 years prior to screening and after the onset of chronic cough, chest imaging did not reveal any significant abnormalities that the investigators considered to cause chronic cough or any other clinically significant lung disease;
- VAS scores of cough severity in screening period and baseline period ≥ 40 mm;
- Subjects receiving medication for pre-existing underlying conditions prior to the screening period should stabilize the corresponding dose for at least 8 weeks prior to screening;
- Take effective contraceptive measures;
- Voluntarily sign informed consent to participate in this study;
- Willing and able to comply with all protocol requirements, including demonstrating the ability to comply with study procedures prior to random assignment.
Exclusion Criteria:
- Patients diagnosed with chronic obstructive pulmonary disease (COPD), bronchiectasis, idiopathic pulmonary fibrosis (IPF), and endobronchial tuberculosis;
- Patients with a history of chronic bronchitis;
- Patients with a history of upper or lower respiratory tract infection, or acute exacerbation of respiratory disease, or significant changes in chest imaging within 4 weeks prior to baseline period;
- Current smokers, smokers who have quit smoking (within 6 months), or former smokers who consume more than 20 packs of cigarettes per year;
- Those with abnormal taste within 3 months prior to previous diagnosis or screening;
- Malignant disease within 5 years or less before signing the informed consent, except for basal cell or squamous cell skin cancer or cervical cancer in situ after appropriate treatment;
- Currently taking or having taken an angiotensin-converting enzyme inhibitor in the 3 months prior to screening;
- Those who are currently taking or have used any antitussive medication within the week prior to screening;
- Patients who had used oral steroids or antiallergy drugs within 1 week prior to screening;
- Screening or baseline 1 second rate < 60%;
- Poorly controlled hypertension;
- Alanine aminotransferase or aspartate aminotransferase more than 2 times the upper limit of normal in screening period or baseline period;
- Estimated glomerular filtration rate (eGFR) < 30mL/min/1.73m2 or eGFR≥30mL/min/1.73m2 and <50mL/min/1.73m2 with unstable renal function during screening;
- Use of systemic immunosuppressants or immunomodulators, or biologics or Th2 cytokine inhibitors within 12 weeks prior to randomization or within 5 half-lives of the drug;
- A recent history of drug or alcohol abuse or dependence (within the past 1 year);
- Participants enrolled in clinical trials of any drug or medical device within 3 months prior to screening, or within 5 half-lives of test drugs before screening, whichever is longer;
- Any past or present circumstances, determined by the investigator or sponsor, make the subject unfit for admission to the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HRS-2261 oral tablet
|
HRS-2261 oral tablet, oral, BID
|
Placebo Comparator: Matching placebo to HRS-2261
|
Matching placebo to HRS-2261, oral, BID
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in visual analog Scale (VAS) scores of cough severity after 4 weeks of treatment (Day 28)
Time Frame: Baseline (Day-1),Day 28
|
Baseline (Day-1),Day 28
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes from baseline in patients' overall Impression of Change (PGIC) scale scores after week 1, 2, 3 and 4 of treatment (Day 7, Day 14, Day 21, Day 28)
Time Frame: Day 7, Day 14, Day 21, Day 28
|
Day 7, Day 14, Day 21, Day 28
|
Changes from baseline in the total score of the Leicester Cough Questionnaire (LCQ), which assessed cough-specific quality of life, at 2 and 4 weeks after treatment (Day 14, Day 28)
Time Frame: Baseline (Day-1), Day 14, Day 28
|
Baseline (Day-1), Day 14, Day 28
|
Changes from baseline in the simple cough severity score (CET) at week 1, 2, 3, and 4 after treatment (Day 7, Day 14, Day 21, Day 28)
Time Frame: Day 7, Day 14, Day 21, Day 28
|
Day 7, Day 14, Day 21, Day 28
|
Incidence and severity of any adverse events (AE)
Time Frame: up to 6 weeks (Day 42)
|
up to 6 weeks (Day 42)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 9, 2023
Primary Completion (Estimated)
March 30, 2024
Study Completion (Estimated)
March 30, 2024
Study Registration Dates
First Submitted
February 8, 2023
First Submitted That Met QC Criteria
February 8, 2023
First Posted (Actual)
February 17, 2023
Study Record Updates
Last Update Posted (Actual)
June 6, 2023
Last Update Submitted That Met QC Criteria
June 4, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-2261-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Chronic Cough
-
Trevi TherapeuticsRecruitingRefractory Chronic CoughCanada, United Kingdom
-
Mayo ClinicRecruitingRefractory Chronic CoughUnited States
-
Bellus Health Inc. - a GSK companyRecruitingRefractory Chronic CoughKorea, Republic of, United States, Taiwan, Australia, New Zealand, Czechia, United Kingdom, Germany, Slovakia, India
-
Bellus Health IncTerminatedChronic Refractory CoughUnited States, United Kingdom
-
University Hospital, ToulouseMSD FranceActive, not recruitingRefractory Chronic CoughFrance
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.CompletedRefractory Chronic Cough
-
Afferent Pharmaceuticals, Inc.Completed
-
The First Affiliated Hospital of Guangzhou Medical...Unknown
-
Patara PharmaCompletedRefractory Chronic CoughNetherlands, United Kingdom
Clinical Trials on HRS-2261 oral tablet
-
Guangdong Hengrui Pharmaceutical Co., LtdCompleted
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruitingAdvanced Malignant Tumour
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Atridia Pty Ltd.CompletedInflammatory Bowel DiseaseAustralia
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom